Intestinal Research.2016;14(1):104-105. doi:10.5217/ir.2016.14.1.104
No abstract available.
Intestinal Research
2002 (v1, n1) to Present ISSN: 1671-8925
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
Cutaneous lesions in colorectal carcinoma: a rare presentation.
Intestinal Research.2016;14(1):102-103. doi:10.5217/ir.2016.14.1.102
No abstract available.
Colorectal Neoplasms*
Colorectal Neoplasms*
Cerebral venous thrombosis in a patient with Crohn's disease.
Intestinal Research.2016;14(1):96-101. doi:10.5217/ir.2016.14.1.96
Patients with inflammatory bowel disease (IBD) have an elevated risk of venous thromboembolism compared with the general population. The most common sites of venous thromboembolism in IBD patients are the deep veins of the legs, the pulmonary system, and portal and mesenteric veins. However, cerebral venous thrombosis is rarely associated with IBD. This report describes a case of cerebral venous thrombosis in a patient with Crohn's disease. A 17-year-old girl, diagnosed 4 years earlier with Crohn's disease, presented with headache and vomiting. Magnetic resonance imaging of the brain with venography showed venous thrombosis in the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein. The patient immediately started anticoagulation therapy with intravenous heparin infusion followed by daily oral rivaroxaban 10 mg. Follow-up imaging after 2 weeks showed resolution of the thrombosis, with recanalization of the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein. She continued rivaroxaban therapy for 6 months, and remained well, without neurologic sequelae. A high level of concern for cerebral venous thrombosis may be important when treating active IBD patients, because anticoagulation treatment can prevent fatal complications.
Adolescent ; Brain ; Crohn Disease* ; Female ; Follow-Up Studies ; Headache ; Heparin ; Humans ; Inflammatory Bowel Diseases ; Jugular Veins ; Leg ; Magnetic Resonance Imaging ; Mesenteric Veins ; Phlebography ; Rivaroxaban ; Superior Sagittal Sinus ; Thrombosis ; Veins ; Venous Thromboembolism ; Venous Thrombosis* ; Vomiting
Adolescent ; Brain ; Crohn Disease* ; Female ; Follow-Up Studies ; Headache ; Heparin ; Humans ; Inflammatory Bowel Diseases ; Jugular Veins ; Leg ; Magnetic Resonance Imaging ; Mesenteric Veins ; Phlebography ; Rivaroxaban ; Superior Sagittal Sinus ; Thrombosis ; Veins ; Venous Thromboembolism ; Venous Thrombosis* ; Vomiting
Ischemic enteritis with intestinal stenosis.
Intestinal Research.2016;14(1):89-95. doi:10.5217/ir.2016.14.1.89
A 75-year-old man was admitted to our hospital with sudden onset of vomiting and abdominal distension. The patient was taking medication for arrhythmia. Computed tomography showed stenosis of the ileum and a small bowel dilatation on the oral side from the region of stenosis. A transnasal ileus tube was placed. Enteroclysis using contrast medium revealed an approximately 6-cm afferent tubular stenosis 10 cm from the terminal ileum and thumbprinting in the proximal bowel. Transanal double-balloon enteroscopy showed a circumferential shallow ulcer with a smooth margin and edema of the surrounding mucosa. The stenosis was so extensive that we could not perform endoscopic balloon dilation therapy. During hospitalization, the patient's nutritional status deteriorated. In response, we surgically resected the region of stenosis. Histologic examination revealed disappearance of the mucosal layer and transmural ulceration with marked fibrosis, especially in the submucosal layer. Hemosiderin staining revealed sideroferous cells in the submucosal layers. Based on the pathologic findings, the patient was diagnosed with ischemic enteritis. The patient's postoperative course was uneventful.
Aged ; Arrhythmias, Cardiac ; Constriction, Pathologic* ; Dilatation ; Double-Balloon Enteroscopy ; Edema ; Enteritis* ; Fibrosis ; Hemosiderin ; Hospitalization ; Humans ; Ileum ; Ileus ; Intestines ; Ischemia ; Mucous Membrane ; Nutritional Status ; Ulcer ; Vomiting
Aged ; Arrhythmias, Cardiac ; Constriction, Pathologic* ; Dilatation ; Double-Balloon Enteroscopy ; Edema ; Enteritis* ; Fibrosis ; Hemosiderin ; Hospitalization ; Humans ; Ileum ; Ileus ; Intestines ; Ischemia ; Mucous Membrane ; Nutritional Status ; Ulcer ; Vomiting
Clinical Characteristics and Outcomes of Diverticulitis by Physician's Specialty.
Intestinal Research.2013;11(2):92-99. doi:10.5217/ir.2013.11.2.92
BACKGROUND/AIMS: Several factors affecting the severity and outcomes of diverticulitis have been reported, but there is little research on physician specialty related with this disease. Therefore, we evaluated the clinical characteristics and outcomes of diverticulitis depending on physician's specialty. METHODS: Medical records of 239 patients, who had been hospitalized with first-diagnosed acute colonic diverticulitis at Kyung Hee University Hospital in Gang Dong (Seoul, Korea) from June 2006 to December 2012, were retrospectively analyzed. The patients were classified according to whether they had been managed by gastroenterologists or not. Clinical characteristics and treatment outcomes were compared between two groups. RESULTS: Of these 239 patients, 38 (15.9%) patients were treated by a gastroenterologist and 201 (84.1%) patients by a non-gastroenterologist. Clinical characteristics such as age, gender, body mass index, comorbidity, medication, laboratory results, recurrence and complication were not significantly different between two groups. However, right-sided diverticulitis predominated in the non-gastroenterologist group (79% vs. 91%, P=0.028). From the sub-group analysis of uncomplicated diverticulitis, intravenous antibiotics was used for a shorter period of time by gastroenterologists than non-gastroenterologists (3.3+/-1.9 days vs. 4.4+/-2.8 days, P=0.032). Multivariate logistic regression analysis showed that the 3 day administration of intravenous antibiotics significantly depended on the physician's specialty (odds ratio 7.984, 95% confidence interval 1.990-32.043, P=0.003). CONCLUSIONS: The results suggest that the duration of intravenous antibiotics for treating uncomplicated colonic diverticulitis was shortened by gastroenterology specialists without increasing operation or recurrence.
Anti-Bacterial Agents ; Body Mass Index ; Colon ; Comorbidity ; Diverticulitis ; Diverticulitis, Colonic ; Gastroenterology ; Humans ; Logistic Models ; Medical Records ; Recurrence ; Retrospective Studies ; Specialization ; Specialty Boards ; Treatment Outcome
Anti-Bacterial Agents ; Body Mass Index ; Colon ; Comorbidity ; Diverticulitis ; Diverticulitis, Colonic ; Gastroenterology ; Humans ; Logistic Models ; Medical Records ; Recurrence ; Retrospective Studies ; Specialization ; Specialty Boards ; Treatment Outcome
Stem Cells in Colorectal Cancer: New Potential Therapeutic Target.
Intestinal Research.2013;11(2):85-91. doi:10.5217/ir.2013.11.2.85
Within the crypts of the intestinal mucosa, intestinal epithelium is a permanently renewing tissue, the architecture of which is maintained by the ability of the intestinal stem cells to self-renew and to generate a hierarchy of proliferative and differentiated cells. In the hierarchical structure of intestinal epithelia, the balance between proliferation and cell death is important for homeostasis. This unique structure of intestinal mucosa, crypt axis, is supported by micro-environmental factors, and the disruption of the homeostasis of the crypt axis can develop colorectal neoplasia. Recent evidence suggests that colorectal cancer may arise from mutated colorectal stem or progenitor cells termed colorectal cancer stem cells (CSC) or initiating cells because of their exclusive ability to sustain tumor formation. Colorectal CSC have been identified based on the expression of cell surface markers such as CD133, CD44 and CD166, and these cells have stem/progenitor cell properties, the ability to self-renew, differentiate, and proliferate indefinitely to drive continuous expansion of the malignant cell population. The CSCs, in limited number within the bulk of the tumor, may account for their capability of escaping conventional therapies, thus leading to disease relapse and metastasis. To overcome these malignant features of cancer, the researchers emphasize the importance of better characterizing CSC to target the CSC.
Axis, Cervical Vertebra ; Cell Death ; Colorectal Neoplasms ; Homeostasis ; Intestinal Mucosa ; Neoplasm Metastasis ; Recurrence ; Stem Cells ; United Nations
Axis, Cervical Vertebra ; Cell Death ; Colorectal Neoplasms ; Homeostasis ; Intestinal Mucosa ; Neoplasm Metastasis ; Recurrence ; Stem Cells ; United Nations
Stem Cells in Inflammatory Bowel Disease: New Potential Therapeutic Target.
Intestinal Research.2013;11(2):79-84. doi:10.5217/ir.2013.11.2.79
Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents that selectively target specific molecules or pathways to correct the imbalance of the gut immune system have been developed. Among them, an antibody to tumor necrosis factor (anti-TNF) is the first developed drug which has dramatically improved the management of patients with IBD. However, more than one-third of IBD patients do not respond to medications, and there is the problem of antibody formation. Therefore, enormous efforts have been made into the development of novel anti-cytokines and stem cell injection as an alternative to has been made. However, the efficacy and safety of stem cell treatment are under investigation. Some studies have reported very promising data; however, others have shown conflicting results. In addition, most trials involved a very small number of subjects and did not compare stem cell treatment with anti-TNF. The present paper reviews the function and therapeutic mechanism of stem cells for the treatment of IBD.
Antibody Formation ; Humans ; Immune System ; Inflammatory Bowel Diseases ; Stem Cells ; Tumor Necrosis Factor-alpha
Antibody Formation ; Humans ; Immune System ; Inflammatory Bowel Diseases ; Stem Cells ; Tumor Necrosis Factor-alpha
Fecal Biomarkers in Inflammatory Bowel Disease.
Intestinal Research.2013;11(2):73-78. doi:10.5217/ir.2013.11.2.73
Inflammatory bowel diseases (IBD) are idiopathic, remitting and relapsing diseases causing chronic inflammation of intestine. Initial diagnosis, assessment of disease activity, and prediction of treatment outcomes present challenges to physicians in clinical care of IBD. Therefore it is critical to accurately determine inflammatory activity of the gut. Endoscopy, the current gold standard for assessing and monitoring intestinal inflammation, is costly, invasive and at times, dangerous. Fecal biomarkers are a simple, reliable, non-invasive test that, because of their direct contact with the intestinal mucosa, may be more accurate in determining intestinal inflammation than serum biomarkers. Since calprotectin was identified as a marker for IBD, several additional fecal markers, including lactoferrin, S100A12, and M2-pyruvate kinase, have been evaluated for their ability to differentiate and monitor disease activity. Fecal biomarkers are useful in differentiating IBD from functional bowel disorders, monitoring response to treatment and predicting clinical and endoscopic relapse. Although they may not ever replace endoscopy, fecal markers could minimize unnecessary, potentially dangerous examinations and help guide IBD management in a more cost-effective manner.
Biomarkers ; Endoscopy ; Inflammation ; Inflammatory Bowel Diseases ; Intestinal Mucosa ; Intestines ; Lactoferrin ; Leukocyte L1 Antigen Complex ; Organothiophosphorus Compounds ; Phosphotransferases ; Recurrence
Biomarkers ; Endoscopy ; Inflammation ; Inflammatory Bowel Diseases ; Intestinal Mucosa ; Intestines ; Lactoferrin ; Leukocyte L1 Antigen Complex ; Organothiophosphorus Compounds ; Phosphotransferases ; Recurrence
Intestinal Research.2015;13(1):68-73. doi:10.5217/ir.2015.13.1.68
BACKGROUND/AIMS: Ghrelin levels are known to increase in patients with ulcerative colitis (UC), but serum obestatin levels in UC patients are not well elucidated. The aim of this study was to examine the relationship between serum ghrelin and obestatin levels and disease activity in UC patients. METHODS: The serum ghrelin and obestatin levels were measured in 21 UC patients (12 with active disease and 9 in remission) using enzyme-linked immunosorbent assay. The relationship between the circulating levels of these 2 hormones and disease activity was analyzed. The colonic mucosal mRNA expression of ghrelin and obestatin was measured by quantitative reverse transcription polymerase chain reaction. RESULTS: The mean serum ghrelin values were significantly higher in patients with active disease than in patients with remission (1370.6+/-404.3 vs. 783.5+/-235.3 pg/mL, P=0.001). Colonic mucosal mRNA expression of ghrelin was also significantly higher in patients with active disease than in patients in remission (0.805+/-0.214 vs. 0.481+/-0.356, P=0.018). However, the mean serum obestatin levels and colonic mucosal mRNA expression of obestatin were not significantly different between both groups. The circulating obestatin/ghrelin ratio was significantly lower in patients with active UC than in patients in remission (0.32+/-0.08 vs. 0.58+/-0.20, P=0.001). CONCLUSIONS: The serum ghrelin levels and the obestatin/ghrelin ratio were related to the activity of UC, but serum obestatin was not related to activity of UC. The ghrelin levels and the obestatin/ghrelin ratio could serve as activity markers in patients with UC.
Colitis, Ulcerative* ; Colon ; Enzyme-Linked Immunosorbent Assay ; Ghrelin* ; Humans ; Polymerase Chain Reaction ; Reverse Transcription ; RNA, Messenger
Colitis, Ulcerative* ; Colon ; Enzyme-Linked Immunosorbent Assay ; Ghrelin* ; Humans ; Polymerase Chain Reaction ; Reverse Transcription ; RNA, Messenger
Intestinal Research.2015;13(1):60-67. doi:10.5217/ir.2015.13.1.60
BACKGROUND/AIMS: Despite the rising incidence and prevalence of inflammatory bowel disease (IBD) in Asian populations, data regarding clinical characteristics of patients in Asia based on age at diagnosis are relatively sparse. The aim of this study was to compare clinical characteristics based on the age at diagnosis according to the Montreal Classification in Korean IBD patients. METHODS: We recruited consecutive patients with IBD at two tertiary hospitals and retrospectively reviewed their medical information. Patients were divided into three groups according to their age at diagnosis: youth (<17 years), young adult (17-40 years), and middle-old (>40 years). The main clinical characteristics for comparison were the achievement of a remission state at the last follow-up visit, cumulative rate of surgery, and cumulative use of immunomodulators and tumor necrosis factor-alpha (TNFalpha) blockers during the follow-up period. RESULTS: In total, 346 IBD patients were included (Crohn's disease [CD] 146 and ulcerative colitis 200; 36 youth, 202 young adult, and 113 middle-old). The middle-old group with CD was characterized by a predominance of uncomplicated behavior (P=0.013) and a lower frequency of perianal disease (P=0.009). The middle-old group was associated more with a less aggressive disease course than the younger group, as shown by more frequent remission (P=0.004), being less likely to undergo surgery (P<0.001), and lower cumulative use of immunomodulators and TNFalpha blockers (P<0.001). CONCLUSIONS: Age at diagnosis according to the Montreal Classification is an important prognostic factor for Korean IBD patients.
Adolescent ; Age of Onset ; Asia ; Asian Continental Ancestry Group ; Classification ; Colitis, Ulcerative ; Crohn Disease ; Diagnosis* ; Follow-Up Studies ; Humans ; Immunologic Factors ; Incidence ; Inflammatory Bowel Diseases* ; Prevalence ; Prognosis ; Retrospective Studies ; Tertiary Care Centers ; Tumor Necrosis Factor-alpha ; Young Adult
Adolescent ; Age of Onset ; Asia ; Asian Continental Ancestry Group ; Classification ; Colitis, Ulcerative ; Crohn Disease ; Diagnosis* ; Follow-Up Studies ; Humans ; Immunologic Factors ; Incidence ; Inflammatory Bowel Diseases* ; Prevalence ; Prognosis ; Retrospective Studies ; Tertiary Care Centers ; Tumor Necrosis Factor-alpha ; Young Adult
Country
Republic of Korea
Publisher
Korean Association for the Study of Intestinal Diseases
ElectronicLinks
http://synapse.koreamed.org/LinkX.php?code=0143IREditor-in-chief
You Sun Kim
thekasid@irjournal.org
Abbreviation
Intest Res
Vernacular Journal Title
ISSN
1598-9100
EISSN
2288-1956
Year Approved
2008
Current Indexing Status
Currently Indexed
Start Year
Description
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include colon and small intestine cancer or polyp, inflammatory bowel disease, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth.
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)